"Hepatocellular carcinoma: A life-threatening disease".
An estimated rise in liver cancer incidence will increase to 95374 new cases by 2020. Hepatocellular Carcinoma (HCC), the most common primary malignant tumour of the liver, is considered to be the third leading cause of all cancer-related deaths and fifth common cancer worldwide. The reported data shows that the rate of HCC incidence in male population is three to four times higher compared with the female population. In the United States, HCV-induced liver cancer is increasing very fast because of the lack of proper treatment option. There are various treatment strategies available for HCC like liver transplantation, resection, ablation, embolization and chemotherapy still the prognosis is destitute. If the patient is eligible, liver transplantation is the only therapeutic option that may give around 90% survival rate, but the scarcity of liver donor limits its broad applicability. A sudden address is necessary to develop specific drugs, personalized medicine, for HCC.
Division of Pharmaceutical Chemistry, Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi, Jharkhand 835215, India. Electronic address: shinu10015@bitmesra.ac.in.
Shinu
S
Chacko
Division of Pharmaceutical Chemistry, Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi, Jharkhand 835215, India.
Subir
S
Samanta
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D063646:Carcinogenesis / Q000473:pathology; D006528:Carcinoma, Hepatocellular / Q000453:epidemiology / Q000473:pathology* / Q000628:therapy; D006801:Humans; D007167:Immunotherapy; D008113:Liver Neoplasms / Q000453:epidemiology / Q000473:pathology* / Q000628:therapy; D058990:Molecular Targeted Therapy
D000970:Antineoplastic Agents
Hepatocellular carcinoma; Immunotherapy; Molecular targeted therapy; Peptide hybrid; Personalized medicine; Transarterial chemoembolization